MISONIX, INC. (NASDAQ:MSON) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure
On March 13, 2017, Misonix, Inc. (the Company) issued a press
release announcing the filing of its Forms 10-Q for the quarters
ended September 30, 2016 and December 31, 2016 and providing
certain information contained therein. The press release is
attached hereto as Exhibit 99.1. The information in this Item and
the aforementioned press release shall not be deemed filed for
purposes of Section 18 of the Exchange Act, and is not
incorporated by reference into any filing of the Company, whether
made before or after the date of this report, regardless of any
general incorporation language in the filing.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release dated March 13, 2017 |
About MISONIX, INC. (NASDAQ:MSON)
MISONIX, INC. (Misonix) is a surgical device company. The Company designs, manufactures and markets therapeutic ultrasonic products across the world for spine surgery, skull-based surgery, neurosurgery, wound and burn debridement, cosmetic surgery, laparoscopic surgery and other surgical applications. The Company’s products include BoneScalpel, BoneScalpel MIS System, SonicOne O.R. System and SonaStar. BoneScalpel is an ultrasonic cutting system with applications in orthopedic and reconstructive surgery, as well as neurosurgery. BoneScalpel MIS System offers deep cuts through osseous structures with minimal blood loss. Misonix SonicOne O.R. System is an ultrasonic surgical debridement system that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonaStar is used for neurosurgical procedures, such as skull/non-skull base tumor resections, transnasal procedures and acoustic mengiomas. MISONIX, INC. (NASDAQ:MSON) Recent Trading Information
MISONIX, INC. (NASDAQ:MSON) closed its last trading session up +0.20 at 11.55 with 8,379 shares trading hands.
